Skip to content
value.today

Grace Therapeutics, Inc.

GRCE
$39 Mmarket cap on Oct 28, 2026
Compare
World rank
#22,113
Revenue
—
For year ending March-2026
Net income
$-8 M
SEC filing
Employees
—

Grace Therapeutics, Inc. in brief

Grace Therapeutics, Inc. is a listed company in the Biotechnology industry, based in Princeton, New Jersey, USA. Its market value was $39 M on 28 October 2026, which makes it the 22,113th largest listed company in the world and the 3,959th largest in the USA on this site. Its shares trade under the symbol GRCE (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Grace Therapeutics, Inc.

We are focused on developing and commercializing products for rare and orphan diseases that have the potential to improve clinical outcomes by using our novel drug delivery technologies. We seek to apply new proprietary formulations to approved and marketed pharmaceutical compounds to achieve enhanced efficacy, faster onset of action, reduced side effects, more convenient drug delivery and increased patient compliance; all of which could result in improved patient outcomes. The active pharmaceutical ingredients used in the drug candidates under development by us may be already approved in a target indication or could be repurposed for use in new indications.

From the company's annual report filed with the US SEC: read the report

Grace Therapeutics, Inc. timeline

2 events, 2008–2024
  1. 2008
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 2024
  4. ✎
    Renamed Grace Therapeutics, Inc.
    Formerly Acasti Pharma Inc..

Events of Grace Therapeutics, Inc. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$11 M$23 M$34 M$45 M

World rank over time

▼ down 159 places since 2026
2026-10-14: #21991#21,99120262026-10-28: #22150#22,1502026

Rank in USA: #3,909 (Oct 2026) · #3,963 (Oct 2026)

Key ratios

market cap and latest results
P/E ratio
n/m (loss)
Price / sales
—
Price / book
0.6×
Free cash flow yield
-25.7%
Net margin
—
Operating margin
—
Return on equity
-12.2%
Liabilities / assets
4.1%
Revenue growth
+49900.0%
R&D / revenue
5.6%

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Mar 2019: revenue —, net income $-39M—FY19Fiscal year ending Mar 2020: revenue —, net income $-26M—FY20Fiscal year ending Mar 2021: revenue $0M, net income $-20M$0MFY21Fiscal year ending Mar 2022: revenue $100M, net income $-10M$100MFY22Fiscal year ending Mar 2023: revenue —, net income $-42M—FY23Fiscal year ending Mar 2024: revenue —, net income $-13M—FY24Fiscal year ending Mar 2025: revenue —, net income $-10M—FY25Fiscal year ending Mar 2026: revenue —, net income $-8M—FY26
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Mar 2026——$-11M$-8M—
Mar 2025——$-17M$-10M—
Mar 2024——$-13M$-13M—
Mar 2023——$-52M$-42M—
Mar 2022$100M+49900.0%$-16M$-10M-9.8%
Mar 2021$0M—$-16M$-20M-9840.0%
Mar 2020——$-24M$-26M—
Mar 2019——$-34M$-39M—

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Mar 2026$-9M——$-0.47—
Mar 2025$-15M——$-0.79—
Mar 2024$-12M——$-1.35—
Mar 2023$-16M——$-5.71—
Mar 2022$-17M——$-0.27—
Mar 2021$-14M——$-1.33—
Mar 2020$-23M——$-0.30—
Mar 2019———$-0.73—

Quarterly results

USD · three months to · source: SEC filings
RevenueNet income
Three months to Dec 2024: revenue —, net income $-4M—Dec ’24Three months to Mar 2025 (from the annual report): revenue —, net income $1M—Mar ’25Three months to Jun 2025: revenue —, net income $-3M—Jun ’25Three months to Sep 2025: revenue —, net income $-1M—Sep ’25Three months to Dec 2025: revenue —, net income $-2M—Dec ’25Three months to Mar 2026 (from the annual report): revenue —, net income $-1M—Mar ’26Three months to Jun 2026: revenue —, net income $-16M—Jun ’26Three months to Sep 2026: revenue —, net income $-2M—Sep ’26

Latest quarter to Sep 2026: revenue —, net income $-2M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

SEC filings

Official filings of Grace Therapeutics, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
—
Operating income
$-11 M
Net income
$-8 M

For year ending March-2026 · source: SEC filing

Balance sheet

Total assets
$67 M
Total liabilities
$3 M
Total equity
$64 M

As of March-2026

Top 38 institutional investors in Grace Therapeutics, Inc.#

As of Sep 30, 2026
38 institutions held 7.6 M shares (about 36.1% of the shares outstanding) on Sep 30, 2026. The ten largest hold 33.5%. Source: SEC Form 13F filings, filed through Nov 16, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in Grace Therapeutics, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1Opaleye Management Inc.2,798,167New13.30%$6 MNov 16, 2026
2Cerity Partners LLC849,0550 (0.00%)4.04%$2 MNov 13, 2026
3Eversept Partners, LP769,772-3,128 (-0.40%)3.66%$2 MNov 16, 2026
4Bank Of America Corp /de/494,6980 (0.00%)2.35%$1 MNov 16, 2026
5Nantahala Capital Management, LLC476,190New2.26%$1 MNov 13, 2026
6Rosalind Advisors, Inc.476,190New2.26%$1 MNov 16, 2026
7ADAR1 Capital Management, LLC476,190New2.26%$1 MNov 16, 2026
8Vanguard Capital Management LLC400,350-11,364 (-2.76%)1.90%$1 MNov 13, 2026
9Renaissance Technologies LLC186,134New0.88%$0 MNov 12, 2026
10Two Sigma Investments, LP126,791+29,901 (+30.86%)0.60%$0 MNov 16, 2026
11Cantor Fitzgerald, L. P.100,000-100,000 (-50.00%)0.48%$0 MNov 16, 2026
12Citadel Advisors LLC66,696-283,044 (-80.93%)0.32%$0 MNov 16, 2026
13Jane Street Group, LLC62,725-26,717 (-29.87%)0.30%$0 MNov 12, 2026
14Susquehanna International Group, LLP55,319+5,742 (+11.58%)0.26%$0 MNov 16, 2026
15BlackRock, Inc.35,915-1,620 (-4.32%)0.17%$0 MNov 13, 2026
16XTX Topco Ltd35,772-35,896 (-50.09%)0.17%$0 MNov 16, 2026
17Citigroup Inc35,481New0.17%$0 MNov 4, 2026
18Rangeley Capital, LLC25,208-792 (-3.05%)0.12%$0 MNov 16, 2026
19Kestra Private Wealth Services, LLC23,0000 (0.00%)0.11%$0 MNov 6, 2026
20Morgan Stanley22,763+13,315 (+140.93%)0.11%$0 MNov 13, 2026
21Johnson Dunn Capital Advisors Inc19,500—0.09%$0 MNov 12, 2026
22BNP Paribas Financial Markets15,900+5,400 (+51.43%)0.08%$0 MNov 12, 2026
23Axq Capital, LP12,221New0.06%$0 MNov 12, 2026
24Oppenheimer & Co Inc10,0000 (0.00%)0.05%$0 MOct 26, 2026
25Vanguard Fiduciary Trust Co8,7500 (0.00%)0.04%$0 MNov 13, 2026
Show all 38: investors 26 to 38
Institutional investors 26 to 38 in Grace Therapeutics, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
26National Bank Of Canada /fi/2,6800 (0.00%)0.01%$0 MNov 16, 2026
27UBS Group AG2,289-14,488 (-86.36%)0.01%$0 MNov 10, 2026
28Tower Research Capital LLC (TRC)2,258+606 (+36.68%)0.01%$0 MNov 16, 2026
29Royal Bank Of Canada898+355 (+65.38%)0.00%$0 MNov 16, 2026
30Nuveen, LLC863New0.00%$0 MNov 10, 2026
31Arax Advisory Partners250-750 (-75.00%)0.00%$0 MNov 12, 2026
32Activest Wealth Management1040 (0.00%)0.00%$0 MOct 15, 2026
33SBI Securities Co., Ltd.770 (0.00%)0.00%$0 MOct 22, 2026
34Jpmorgan Chase & Co58New0.00%$0 MNov 12, 2026
35Harbour Investments, Inc.37New0.00%$0 MNov 9, 2026
36Osaic Holdings, Inc.31New0.00%$0 MNov 12, 2026
37Lanark Financial, Inc.20 (0.00%)0.00%$0 MOct 26, 2026
38Caitong International Asset Management Co., Ltd1New0.00%$0 MOct 29, 2026

Mutual funds holding Grace Therapeutics, Inc.#

7 funds hold shares worth $1 M (about 2.2% of the company). Since their previous reports 5 added shares and 0 sold, buying $0 M net.
Mutual funds holding Grace Therapeutics, Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.400,350$1 M1.9%<0.01%no changeJun 30, 2026
🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors35,188$0 M0.17%<0.01%newJun 30, 2026
🇺🇸 Tiff Multi-Asset FundTIFF Advisory Services, LLC16,239$0 M0.08%<0.01%+2.2%Jun 30, 2026
🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc.11,364$0 M0.05%<0.01%+770%Jun 30, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC5,571$0 M0.03%<0.01%no changeMay 31, 2026
🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC2,347$0 M0.01%<0.01%newJun 30, 2026
🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC778$0 M<0.01%<0.01%newJun 30, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jun 30, 2026. The 7 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Grace Therapeutics, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$891 K
25 purchases, 2 insiders
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$891 K
open market only
Insiders on file
4
since
$456 K$0Aug 2026: bought $24 K (1 trades), sold $0 (0 trades)Aug 26Sep 2026: bought $294 K (6 trades), sold $0 (0 trades)SepOct 2026: bought $456 K (12 trades), sold $0 (0 trades)OctNov 2026: bought $116 K (6 trades), sold $0 (0 trades)Nov
Bought (open market)Sold (open market)Hover a month for the totals
Grace Therapeutics, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Opaleye Management Inc.10% ownerBuyindirect+2,974$1.725$5 K3.10 MForm 4
filed Opaleye Management Inc.10% ownerBuyindirect+29,207$1.722$50 K3.10 MForm 4
filed Opaleye Management Inc.10% ownerBuyindirect+15,879$1.764$28 K3.07 MForm 4
filed Opaleye Management Inc.10% ownerBuyindirect+3,087$1.775$5 K3.05 MForm 4
filed Opaleye Management Inc.10% ownerBuyindirect+5,027$1.802$9 K3.05 MForm 4
filed Opaleye Management Inc.10% ownerBuyindirect+10,328$1.789$18 K3.05 MForm 4
filed Opaleye Management Inc.10% ownerBuyindirect+66,411$1.768$117 K3.04 MForm 4
filed Opaleye Management Inc.10% ownerBuyindirect+21,390$1.926$41 K2.97 MForm 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Grace Therapeutics, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
1.7 M
10.4% of shares · 12.33 days to cover
Shares sold short, last 24 reportsAll stocks →

Trading halts

  • 2026-04-23 17:52 UTC, code LUDP, resumed 17:57 UTC
  • 2026-04-23 17:46 UTC, code LUDP, resumed 17:51 UTC
  • 2026-04-23 16:27 UTC, code T3, resumed 17:40 UTC

Fails to deliver

  • : 772 shares at $1.87
  • : 1,453 shares at $1.93
  • : 5,517 shares at $1.97
  • : 5,162 shares at $1.99
  • : 1,291 shares at $2.02

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Grace Therapeutics, Inc. scorecard#

Passes 3 of the 12 checks that could be worked out: strongest in valuation (1 of 4), weakest in profitability (0 of 3). Fiscal year 2025; market cap of Oct 28, 2026.

  • Valuation1 of 4
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✓Price to book below its peers' median0.6×Price to book 0.6× against Biotechnology's median of 2.9×.
    • –Price to sales below its peers' medianNo Price to sales on file.
    • ✗Free cash flow yield above 5%-25.7%Free cash flow is -25.7% of the market value.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth1 of 2
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✗Earnings per share grew in the newest year-0.47 vs -0.79Diluted EPS -0.47 in fiscal 2025 against -0.79 the year before (report's currency).
    • ✓Net income higher than five years earlier-$8 M-$8 M in fiscal 2025 against -$20 M in 2020.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 3
    • ✗Profitable in the newest year-$8 MNet income -$8 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • –Operating margin above its peers' medianNo operating margin on file.
    • ✗Return on equity above 15%-11.9%-11.9% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health1 of 2
    • ✓Short-term assets cover short-term liabilities8.1×Current ratio 8.08 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year36.6%Diluted shares up 36.6% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Grace Therapeutics, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in millions of each column's currency; per-share figures in the column's currency; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Grace Therapeutics, Inc.: statements by fiscal year
PeriodTrendFY 2025to Mar 31, 2026 · USDFY 2024to Mar 31, 2025 · USDFY 2023to Mar 31, 2024 · USDFY 2022to Mar 31, 2023 · USDFY 2021to Mar 31, 2022 · USDFY 2020to Mar 31, 2021 · USDFY 2019to Mar 31, 2020 · USDFY 2018to Mar 31, 2019 · USDFY 2017to Mar 31, 2018 · CADFY 2016to Feb 28, 2017 · CAD
Income statement
Revenue————100r0.2————
Cost of revenue————00.1————
Research and development2.49.54.710.05.64.21629167.2
Selling and marketing——0.30.70.51.12.70.5——
General and administrative8.77.26.7r7.69.35.55.84.5——
Operating income−11−17−13−52−16−16−24−34−20−10
Interest and finance income0.70.70.90.20.10.10.30.40.10.1
Interest expense and finance costs————————1.8r0.1r
Other non-operating income (expense)1.63.9−1.80.25.1−3.3−1.1−5.0——
Income before tax−9.5−13−15−52−10−20−26−39——
Income tax−1.7−3.2−1.8−9.5−0.6000—−0.1
Net income including minority interests————————−22−10
Net income attributable to shareholders−7.8−9.6−13−42−9.8−20−26−39——
Earnings per share, basic-0.47-0.79-1.35-5.71r-0.27-1.33r-0.30-0.73——
Earnings per share, diluted-0.47-0.79-1.35-5.71r-0.27-1.33r-0.30-0.73——
Shares, weighted average (basic)17129.57.4r37——541711
Shares, weighted average (diluted)17129.57.4r3715r8554——
Balance sheet
Cash and cash equivalents17222328305114178.211
Short-term investments——00.0139.8—8.9——
Receivables——0.70.80.50.50.51.20.80.2
Other current assets——————0.20.00.1—
Current assets1723242945r6218r289.511
Property, plant and equipment0.00.00.00.1r21—1.92.12.82.8
Right-of-use (leased) assets——00.50.30.10.1———
Goodwill8.18.18.18.113—————
Other intangible assets414141417004.26.4——
Long-term investments———————0.0——
Total assets677273791296223372326
Accounts payable0.70.61.01.21.7r0.1r1.7r3.06.72.4
Current liabilities2.11.91.73.43.31.67.4146.72.4
Lease liabilities (non-current)——00.40.2—0.1———
Total liabilities2.85.41211206.89.926154.0
Retained earnings−228−221−211−198−156−146−126−101−72−50
Shareholders' equity64676268108561311——
Total equity————————8.222
Total liabilities and equity677273791296223372326
Shares outstanding16149.47.4r44—————
Cash-flow statement
Share-based compensation0.80.70.91.81.31.22.0—0.90.6
Cash from operating activities−8.9−15−12−16−17−14−23—−13−6.2
Capital expenditure————————−0.5−2.5
Cash from investing activities000.113−3.5−9.98.1—−0.46.9
Shares issued——00.30597.0—115.0
Cash from financing activities3.7147.40.305913—116.9
Exchange-rate effect on cash————————−0.0−0.1
Change in cash−5.2−0.9−4.9−2.5−2137−2.6—−1.57.5
Report10-K10-K10-K10-K10-K10-K10-K10-K20-F20-F

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

Executive pay at Grace Therapeutics, Inc.#

From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.

CEO total pay, fiscal 2026
$1.3 M
Mr. Kohli
Other top executives, average
$466 K
the CEO earned 2.7× this
$100 invested is now
$63
Grace Therapeutics, Inc.: executive pay by fiscal year
Fiscal yearCEO total payActually paidOther executives, average$100 invested
2026Mr. Kohli$1.3 M$1.9 M$466 K$63
2025Mr. Kohli$1.1 M$775 K$432 K$31
2024Chief executive$998 K$1.2 M$430 K$47

Source: SEC proxy statement (Form DEF 14A) · as of Mar 31, 2026

Events at Grace Therapeutics, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.

Directors and officers 2 · Material agreement 2 · Unregistered share sale 2 · Bylaws or fiscal year changed 1 · Shareholder vote 2 · Results announced 9

Grace Therapeutics, Inc.: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Shareholder vote8-K
Results announced8-K
Material agreementUnregistered share sale8-K
Results announced8-K
Directors and officers8-K
Results announced8-K
Directors and officers8-K
Results announced8-K
Shareholder vote8-K
Results announced8-K
Results announced8-K
Results announced8-K
Material agreementUnregistered share sale8-K
Results announced8-K
Bylaws or fiscal year changed8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 12, 2026

Acquisitions and funding#

Private share sales · funding history

Private share sales of Grace Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Aug 2026$10 MPrivate placement after listing$10 to $50 million9equitySEC
Feb 2025$15 MPrivate placement after listing$10 to $50 million14equity, optionsSEC
Sep 2023$8 MPrivate placement after listing$2 to $10 million4equity, optionsSEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

How Grace Therapeutics, Inc. compares in Biotechnology

  • Market cap$39 M · higher than 24% of 726
  • Price / book0.6× · lower than 89% of 534
  • FCF yield-25.7% · higher than 38% of 449

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Grace Therapeutics, Inc.🇺🇸$39 M———
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 28, 2026
Annual results:
For year ending March-2026
Balance sheet:
As of March-2026
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research, SEC annual report, GLEIF register; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Grace Therapeutics, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Grace Therapeutics, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Grace Therapeutics, Inc.? Suggest a correction